TruScreen’s real time technology has been found to be twice as sensitive as the Pap test and significantly more sensitive than HPV DNA testing at defining high grade cervical lesions in a real world setting.

Millions of women worldwide are unable to access cervical cancer screening.

Millions of women worldwide are unable to access cervical cancer screening.

Pap smear tests are ineffective in low-resource or developing health economies due to a lack of infrastructure, highly trained personnel required to read the smear and delays in reporting results, particularly in remote locations. Each year more than 270,000 women die from this disease.

Learn more

Cervical cancer is a major cause of morbidity and mortality worldwide.

Cervical cancer is a major cause of morbidity and mortality worldwide.

It is the fourth most common cancer affecting women. The death toll is greatest in populations that lack cervical cancer screening programmes. Worldwide, there are approximately 570,000 new cases of cervical cancer diagnosed, and more than 311,000 die from this disease each year.

Learn more

TruScreen has been clinically tested by over 40,000 women around the world.

TruScreen has been clinically tested by over 40,000 women around the world.

Studies have involved women from Australia, Brazil, Italy, Philippines, People’s Republic of China, Russia, Singapore, Vietnam, South Africa, Spain, United Kingdom and the United States of America. More than 25 clinical trials involving 40,000 women have been completed worldwide.

Learn more

Better access to cervical cancer screening will save thousands of lives.

Better access to cervical cancer screening will save thousands of lives.

Cervical cancer develops from slowly progressing intraepithelial lesions. If early changes in cervical cells are detected through screening programmes, cervical cancer is curable. However, if undetected until late in its clinical course, it has a high death rate.

Learn more

TruScreen supports cervical screening in remote areas and developing countries.

TruScreen supports cervical screening in remote areas and developing countries.

For many women in remote areas and developing countries, poor access to cervical screening in clinics means many women go undetected until it is too late. TruScreen's device is mobile and easy to use and does not require lab facilities in order to diagnose women.

Learn more

TruScreen performs equal to, or better than, alternative cervical screening tool

TruScreen performs equal to, or better than, alternative cervical screening tool

The performance of TruScreen has been tested in over 25 clinical trials involving 40,000 women worldwide and was consistent and equal to, or better than in some studies, the comparing high-quality cytology tests within the same study.

Learn more

Cervical cancer can and should be prevented.  TruScreen provides an accurate, real-time screening solution. Our screening solution is ideal for communities that can’t access conventional laboratory dependant screening methods.  It is affordable and easy to learn.  Our purpose is to ensure that all women of screening age have access to quality screening.

Back to top